Clinical trial
Pan Tumor Rollover Study
NCT03899155 · Bristol-Myers Squibb, Industry · Recruiting
Key facts
| NCT number | NCT03899155 |
|---|---|
| Title | Pan Tumor Rollover Study |
| Official title | Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Exelixis Industry Novartis Clovis Oncology, Inc. Janssen Pharmaceuticals |
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Capecitabine, Bevacizumab, Temozolomide, Rucaparib and 9 more |
| Enrollment | 1,500 |
| Start date | May 5, 2020 |
| Primary completion | Aug 25, 2029 |
| Completion | Aug 25, 2029 |
| First posted | Apr 2, 2019 |
| Last update posted | Feb 11, 2026 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France and 26 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: